Company intelligence / Profile preview

Immunas Pharma

Kawasaki, Kanagawa, Japanbloomberg.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Immunas Pharma was a Japanese biotech focused on biological therapies for nervous system diseases, notably developing KHK-6640 targeting beta amyloid A4 protein for Alzheimer’s disease. The company was merged into OncoTherapy Science in March 2024 and is no longer active as an independent entity.[3][6] Clinical development reached Phase 1; no commercialized drugs or recent trial results are available.[3][6]

Therapeutic areas: Neurology
Modalities: Biological products
Industry: Biotech

Drug pipeline

1 asset

anti-amyloid beta peptide antibody

Preclinical

Partnerships

MBL

Beyond the preview

Go deeper on Immunas Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunas Pharma.

Explore the full profile